

Supplementary Note 1 | List of abbreviations.

3'SS, 3' splice site; **5'SS**, 5' splice site; **AD**, Alzheimer disease; **AMBRA1**, autophagy and beclin 1 regulator 1; **AML**, acute myeloid leukemia; **AMPK**, AMP-activated protein kinase; **APOC3**, apolipoprotein C3; **APP**, amyloid beta precursor protein; **ASO**, antisense oligonucleotide; **ATAT1**, alpha tubulin acetyltransferase 1; **ATG**, autophagy related; **ATG16L1**, autophagy related 16 like 1; **ATL3**, Atlastin GTPase 3; **BCL2L1**, BCL2 like 1; **CCD**, coiled-coil domain; **BNIP3**, BCL2 interacting protein 3; **BNIP3L**, BCL2 interacting protein 3 like; **CCPG1**, cell cycle progression 1; **ccRCC**, clear cell renal cell carcinoma; **CEBPB**, CCAAT enhancer binding protein beta; **CMA**, chaperone-mediated autophagy; **CMMI**, chronic myelomonocytic leukemia; **CP**, cleavage and polyadenylation; **CQ**, chloroquine; **DS**, Down syndrome; **ER**, endoplasmic reticulum; **ESE**, exonic splicing enhancer; **ESS**, exonic splicing silencers; **FOXO1**, forkhead box O1; **GABARAP**, GABA type A receptor-associated protein; **H3K36me3**, trimethylation of lysine 36 on histone H3; **H3K4me3**, trimethylation of lysine 4 on histone H3; **HCV**, hepatitis C virus; **HDAC6**, histone deacetylase 6; **hnRNP**, heterogeneous ribonucleoprotein; **HSPA8**, heat shock protein family A (Hsp70) member 8; **HSP8A**, heat shock protein family A (Hsp70) member 8; **IFNL2**, interferon lambda 2; **LAP**, LC3-associated phagocytosis; **LAMP2**, lysosomal associated membrane protein 2; **LIR**, LC3-interacting region; **MAP1LC3/LC3**, microtubule associated protein 1 light chain 3; **MBNL**, muscleblind like splicing regulator; **MDS**, myelodysplastic syndrome; **MFN2**, mitofusin 2; **MORF4L1**, mortality factor 4 like 1; **MTOR**, mechanistic target of rapamycin kinase; **PD**, Parkinson disease; **PE**, phosphatidylethanolamine; **PINK1**, PTEN induced kinase 1; **PIK3C3**, phosphatidylinositol 3-kinase catalytic subunit type 3; **PIK3R4**, phosphoinositide-3-kinase regulatory subunit 4; **Poly(A)**, polyadenylation; **PRKN**, parkin RBR E3 ubiquitin protein ligase; **PRPF8**, pre-mRNA processing factor 8; **PSEN1**, presenilin 1; **PTBP1**, polypyrimidine tract binding protein 1; **PtdIns3K**, class III phosphatidylinositol 3-kinase; **PtdIns3P**, phosphatidylinositol-3-phosphate; **PTEN**, phosphatase and tensin homolog; **RAB33B**, RAB33B, member RAS oncogene family; **RBCC1**, RB1-inducible coiled-coil protein 1; **RBFOX2**, RNA binding fox-1 homolog 2; **RBP**, RNA-binding protein; **RETREG1**, reticulophagy regulator 1; **RELA**, RELA proto-oncogene, NF- κ B subunit; **RTN3**, reticulon 3; **RUBCN**, rubicon autophagy regulator; **SENDA**, static encephalopathy of childhood with neurodegeneration in adulthood; **SETD2**, SET domain containing 2, histone lysine methyltransferase; **SF1**, splicing factor 1; **SMAC**, single-membrane Atg8-family protein conjugation; **SNAP29**, synaptosome associated protein 29; **SNARE**, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; **SEC62**, SEC62 homolog, preprotein translocation factor; **SMA**, spinal muscular atrophy; **SMN1**, survival of motor neuron 1, telomeric; **SMN2**, survival of motor neuron 2, centromeric; **snRNA**, small nuclear RNA; **snRNP**, small nuclear ribonucleoprotein; **SNRPD1**, small nuclear ribonucleoprotein D1 polypeptide; **SNRPE**, small nuclear ribonucleoprotein polypeptide E; **SNRNP200**, Small Nuclear Ribonucleoprotein U5 Subunit

200; **SQSTM1/p62**, sequestosome 1; **SRSF**, serine and arginine rich splicing factor; **STX17**, syntaxin 17; **TEX264**, testis expressed 264, ER-phagy receptor; **TRIB3**, Tribbles Pseudokinase 3; **Ub**, ubiquitin; **Ubl**, ubiquitin like; **ULK1**, unc-51 like autophagy activating kinase 1; **U2AF**, U2 small nuclear RNA auxiliary factor; **VAMP8**, vesicle associated membrane protein 8; **WDFY3**, WD Repeat And FYVE Domain Containing 3; **WDR45**, WD repeat domain 45; **WIPI**, WD repeat domain, phosphoinositide-interacting; **XBP1**, X-box binding protein 1; **ZFYVE1**, zinc finger FYVE-type containing 1.

Supplementary Table 1 | Alteration in the alternative splicing of autophagy-related genes and impact on diseases

| Autophagy-related gene | Variants | RNA splicing event(s) | Cellular function/phenotype | Disease-associated variants | References |
|------------------------|-------------------------------------------------|-------------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------|
| Initiation | | | | | |
| <i>ULK1</i> | <i>ULK1(1) – canonical variant</i> | 28 exons | Autophagy induction and autophagosome biogenesis | Cancer; neurodegenerative diseases; neurodevelopment disorders; Crohn disease | ¹ |
| | <i>ULK1(2) – generated by splicing mutation</i> | Skipping exon 22 | Mitophagosome formation. Hypoxia-induced mitophagy | Autosomal dominant retinitis pigmentosa | ² |
| | <i>ULK1(3) – generated by splicing mutation</i> | Skipping exon 22-23 | Mitophagosome formation. Hypoxia-induced mitophagy | Autosomal dominant retinitis pigmentosa | ² |
| Nucleation | | | | | |
| <i>BECN1</i> | <i>BECN1 Long – canonical variant</i> | 12 exons | Autophagy induction | - | ^{1,3-6} |
| | <i>BECN1S – generated by splicing mutation</i> | Skipping exon 11; truncated C-terminus | Low binding affinity with class III PtdIns3K; Fail to activate autophagic response to starvation | Prostate cancer; Acute myeloid leukemia; acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia cells | ^{1,7,8} |
| | <i>BECN1s – generated by splicing mutation</i> | Skipping exons 10-11 | Unable to initiate autophagy, but supports mitophagy | Acute myeloid leukemia | ^{1,7,8} |

| | | | | | |
|--------------|---------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-------|
| <i>ATG14</i> | <i>ATG14 Long – canonical variant</i> | 9 | Phagophore formation and autophagosome-lysosome fusion | Vici syndrome; Danon disease; cancer; neurodegenerative diseases | 9 |
| | <i>ATG14 Short</i> | Skipping exons 1-3 | Inhibit autophagosome-lysosome fusion | - | |
| <i>WIP11</i> | <i>WIP11α – canonical variant</i> | 13 exons | Recruitment of ATG12–ATG5-ATG16L1 complex to nascent autophagosomes | - | 10,11 |
| | <i>WIP11β</i> | - | Localizes to endosomal and golgi membranes | - | |
| <i>WIP12</i> | <i>WIP12A – canonical variant</i> | 13 exons | Involved in the formation of autophagosomal structures: mediates ER-phagophore contacts: recruits the ATG12–ATG5-ATG16L1 complex. | - | 10,11 |
| | <i>WIP12B</i> | Skipping exon 12; 3' truncation end | Interacts with ATG16L1; required for innate immune response to <i>Salmonella</i> Typhimurium infection | - | |

| | | | | | |
|------------------------------------|--------------------------------------|------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|-------|
| | <i>WIP12C</i> | - | - | - | 10,11 |
| | <i>WIP12D</i> | Skipping exon 2; 3' truncation end | Promotes LC3 lipidation | - | 14 |
| | <i>WIP12E</i> | - | - | - | 11 |
| <i>WIP14</i> | <i>WIP14α –canonical variant</i> | 11 exons | PtdIns3P binding effector, autophagosome biogenesis and size control | Neurological disorders | 15,16 |
| | <i>WIP14β</i> | Skipping exon 3-4 | - | Static encephalopathy of childhood with neurodegeneration in adulthood | 15 |
| | <i>WIP14Δ</i> | Early 3' end termination exon 11 | - | Static encephalopathy of childhood with neurodegeneration in adulthood | 15 |
| <i>Phagophore expansion</i> | | | | | |
| <i>ATG7</i> | <i>ATG7 long – canonical variant</i> | 19 exons | LC3/GABARAP lipidation | Neurodegeneration; hepatic diseases; cardiovascular diseases | 17-19 |

| | | | | | |
|-----------------|-------------------------------------|---------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------|
| | <i>ATG7 short</i> | Skiping exon 17 | Inhibit autophagy. Unable to bind to LC3 | Myelodysplastic syndrome; Acute myeloid leukemia; chronic myelomonocytic leukemia | 20,21 |
| | <i>ATG7 (3)</i> | Skiping exons 17-18 | - | - | 20,21 |
| <i>MAP1LC3A</i> | <i>MAP1LC3A – canonical variant</i> | 4 exons | Autophagosome biogenesis; adaptor selective cargo for autophagy | Alzheimer disease; Machado-joseph disease; cancer | 22 |
| | <i>MAP1LC3A-b</i> | Additional exon | - | - | 22 |
| <i>MAP1LC3B</i> | <i>MAP1LC3B - canonical variant</i> | 4 exons | Autophagosome biogenesis; adaptor selective cargo for autophagy | Hermansky-pudlak syndrome; Parkinson disease 1, autosomal dominant; cancer | 22,23 |
| | <i>MAP1LC3B-a</i> | NAGNAG splice sites of intron 3 | Inhibits interaction and binding with ATG4B | - | 22,23 |
| <i>GABARAP</i> | <i>GABARAP – canonical variant</i> | 4 exons | Autophagosome biogenesis; receptor of selective cargo for autophagy | Stiff-Person syndrome; Machado-joseph disease; Parkinson disease; colorectal carcinoma | 24 |

| | | | | | |
|---------------------------------|---------------------------------------------------|------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------|----------|
| | <i>GABARAP-a</i> | Different 3' end points | Inhibits interaction and binding with ATG4 | - | 24 |
| <i>GABARAPL1</i> | <i>GABARAPL1</i> | 4 exons | Autophagosome biogenesis; receptor of selective cargo for autophagy | Vici syndrome; Alzheimer disease; cancer | 24 |
| | <i>GABARAPL1-a</i> | Different 3' end points | Inhibits interaction and binding with ATG4 | - | 24 |
| Autophagosome completion | | | | | |
| <i>ATG10</i> | <i>ATG10 long (ATG10L)</i> – canonical variant | 8 exons | Formation of the ATG12–ATG5 complex | Cancer; infection; inflammation | 25-27 |
| | <i>ATG10 short (ATG10S)</i> | Early termination 3'; Skipping exon 4 | Autophagy induction in HCV infection; transcription factor | Hepatitis C virus infection | 25,28,29 |
| <i>ATG12</i> | <i>ATG12 long (ATG12L)</i> | 4 exons | Autophagosome biogenesis; proviral factor; required for HCV translation. | Clear cell renal cell carcinoma; neurodegenerative diseases | 30 |
| | <i>ATG12 short (ATG12S)</i> | Alternative exon 2 | Decrease autophagy flux | SETD2-deficient clear cell renal cell carcinoma | 30 |

| | | | | | |
|----------------|------------------------------------------------------|----------------------------------|-------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------|
| <i>ATG5</i> | <i>ATG5 long</i> | 11 exons | Autophagosome formation, LC3 lipidation and mitochondria quality. | Neurodegenerative diseases; cardiovascular diseases; pathogen infection; immune diseases | 17 |
| | <i>ATG5 Short</i> | Skipping exon 6 or exons 3 and 6 | Unable to form ATG12–ATG5 complex | Prostate DU145 cancer cells | 31,32 |
| | <i>ATG5 short – splice site mutation</i> | Skipping exon 2 | Unable to form ATG12–ATG5 complex | Cervical squamous cell carcinoma | 33 |
| | <i>ATG5 short (1) – splice site mutation</i> | Skipping exon 3, 6 or 7 | Unable to form ATG12–ATG5 complex | Hepatocellular carcinoma | 33 |
| | <i>ATG5 short (2) – splice site mutation</i> | Skipping exon 4 and 7 | Unable to form ATG12–ATG5 complex | Uterine corpus endometrial carcinoma | 33 |
| <i>ATG16L1</i> | <i>ATG16L1α</i> | Skipping exons 8-9 | Unable to lipidate LC3 | Crohn disease; gastric cancer; brain metastasis in lung cancer | 34-38 |
| | <i>ATG16L1β – canonical variant</i> | Skipping exon 9 | ATG12–ATG5 conjugation and LC3 lipidation | Crohn disease; gastric cancer; brain metastasis in lung cancer | 36,39,17,40 |
| | <i>ATG16L1γ</i> | All 20 exons | - | - | 36 |

| | | | | | |
|----------------------------------------|-----------------------------------------|-----------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------|
| <i>ATG16L2</i> | <i>ATG16L2 Long - canonical variant</i> | 18 exons | May play a role in regulating epithelial homeostasis in an ATG16L1-dependent manner | Crohn disease; systemic lupus erythematosus | 17,33,40-42 |
| | <i>ATG16L2 short</i> | Skipping exon 8 | - | - | 42 |
| Autophagosome-lysosome function | | | | | |
| <i>LAMP2</i> | <i>LAMP2A – canonical variant</i> | 9 exons | Involved in CMA | Danon disease; hypertrophic cardiomyopathy; neurological diseases; cancer | 17,43 |
| | <i>LAMP2B</i> | 9 exons | Involved in macroautophagy. Interacts with ATG14 and VAMP8 to promote fusion | Danon disease; hypertrophic cardiomyopathy; renal cell carcinoma | 17,43,44 |
| | <i>LAMP2C</i> | 9 exons | Interact with RBPs and histone 1. Involved in RNautophagy and DNautophagy; negative regulator of CMA | Danon disease; hypertrophic cardiomyopathy | 17,43,45,46 |
| Mitophagy | | | | | |
| <i>PINK1</i> | <i>PINK1L – canonical variant</i> | 8 exons | Located at the mitochondria, involved in mitochondria clearance | Parkinson disease; Alzheimer disease | 47,48 |
| | <i>PINK1-cyto</i> | - | Located at the cytosol. Sequester ubiquitinated proteins into aggresomes | Parkinson disease; Alzheimer disease | 47,48 |

| | | | | | |
|-----------------------------|------------------------------------------------|----------------|---------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-------|
| | <i>PINK1A – splice site mutation in exon 7</i> | Skiping exon 7 | - | - | 49,50 |
| <i>PRKN</i> | <i>PRKN H1 – Canonical variant</i> | 12 exons | Mitophagy | Parkinson disease; Alzheimer disease; cancer | 51,52 |
| | <i>PRKN H2</i> | - | - | - | 52 |
| | <i>PRKN H20</i> | - | - | - | 52 |
| <i>Reticulophagy</i> | | | | | |
| <i>RETREG1/ FAM134B</i> | <i>FAM134B – canonical variant</i> | 9 exons | Located in ER sheets, mediates ER remodeling by direct binding with LC3. Located in brain, spleen and testis. | Neurological diseases; viral replication; inflammation; cancer | 53,54 |
| | <i>RETREG1/FAM134B-2</i> | 6 exons | Regulate selective reticulophagy of secretory proteins. Located in peripheral tissues. | - | 54 |
| <i>RTN3</i> | <i>RTN3L – canonical variant</i> | 9 exons | Interact with MAP1LC3. Promote ER fragmentation and degradation. | Alzheimer disease; astrocytoma | 55,56 |
| | <i>RTN3s</i> | - | Unable to facilitate ER degradation. Induces neurite dystrophy | Alzheimer disease | 55 |

Supplementary References

- 1 Wirawan, E. *et al.* Beclin1: a role in membrane dynamics and beyond. *Autophagy* **8**, 6-17, doi:10.4161/auto.8.1.16645 (2012).
- 2 Xu, G. *et al.* Autosomal dominant retinitis pigmentosa-associated gene PRPF8 is essential for hypoxia-induced mitophagy through regulating ULK1 mRNA splicing. *Autophagy* **14**, 1818-1830, doi:10.1080/15548627.2018.1501251 (2018).
- 3 Yue, Z., Jin, S., Yang, C., Levine, A. J. & Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci U S A* **100**, 15077-15082, doi:10.1073/pnas.2436255100 (2003).
- 4 Qu, X. *et al.* Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest* **112**, 1809-1820, doi:10.1172/jci20039 (2003).
- 5 Zheng, T., Li, D., He, Z., Feng, S. & Zhao, S. Prognostic and clinicopathological significance of Beclin-1 in non-small-cell lung cancer: a meta-analysis. *Onco Targets Ther* **11**, 4167-4175, doi:10.2147/ott.s164987 (2018).
- 6 Nicotra, G. *et al.* Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. *Mod Pathol* **23**, 937-950, doi:10.1038/modpathol.2010.80 (2010).
- 7 Niu, Y. N. *et al.* Alternative messenger RNA splicing of autophagic gene Beclin 1 in human B-cell acute lymphoblastic leukemia cells. *Asian Pacific journal of cancer prevention : APJCP* **15**, 2153-2158 (2014).
- 8 Cheng, B. *et al.* BECN1s, a short splice variant of BECN1, functions in mitophagy. *Autophagy* **11**, 2048-2056, doi:10.1080/15548627.2015.1100785 [doi] (2015).
- 9 Diao, J. *et al.* ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. *Nature* **520**, 563-566, doi:10.1038/nature14147 (2015).
- 10 Dooley, H. C. *et al.* WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1. *Mol Cell* **55**, 238-252, doi:10.1016/j.molcel.2014.05.021 (2014).
- 11 Mauthe, M. *et al.* Resveratrol-mediated autophagy requires WIPI-1-regulated LC3 lipidation in the absence of induced phagophore formation. *Autophagy* **7**, 1448-1461, doi:10.4161/auto.7.12.17802 (2011).
- 12 Jeffries, T. R., Dove, S. K., Michell, R. H. & Parker, P. J. PtdIns-specific MPR Pathway Association of a Novel WD40 Repeat Protein, WIPI49. *Molecular Biology of the Cell* **15**, 2652-2663, doi:10.1091/mbc.e03-10-0732 (2004).
- 13 Stavoe, A. K., Gopal, P. P., Gubas, A., Tooze, S. A. & Holzbaur, E. L. Expression of WIPI2B counteracts age-related decline in autophagosome biogenesis in neurons. *eLife* **8**, doi:10.7554/eLife.44219 (2019).
- 14 Fracciolla, D., Chang, C., Hurley, J. H. & Martens, S. A PI3K-WIPI2 positive feedback loop allosterically activates LC3 lipidation in autophagy. *Journal of Cell Biology* **219**, doi:10.1083/jcb.201912098 (2020).
- 15 Zhao, Y. G. *et al.* The autophagy gene Wdr45/Wipi4 regulates learning and memory function and axonal homeostasis. *Autophagy* **11**, 881-890, doi:10.1080/15548627.2015.1047127 (2015).
- 16 Saitsu, H. *et al.* De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nature genetics* **45**, 445-449, 449e441, doi:10.1038/ng.2562 (2013).
- 17 Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. *Cell* **132**, 27-42 (2008).

- 18 Mortensen, M. *et al.* The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. *J Exp Med* **208**, 455-467, doi:10.1084/jem.20101145 (2011).
- 19 Ilagan, J. O. *et al.* U2AF1 mutations alter splice site recognition in hematological malignancies. *Genome Res* **25**, 14-26, doi:10.1101/gr.181016.114 (2015).
- 20 Greer, S. U. *et al.* Genetic risk of cholangiocarcinoma is linked to the autophagy gene ATG7. *bioRxiv*, 836767, doi:10.1101/836767 (2019).
- 21 Imielinski, M. *et al.* Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* **150**, 1107-1120, doi:10.1016/j.cell.2012.08.029 (2012).
- 22 He, H. *et al.* Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. *The Journal of biological chemistry* **278**, 29278-29287 (2003).
- 23 Liu, C. *et al.* Arginine68 is an essential residue for the C-terminal cleavage of human Atg8 family proteins. *BMC Cell Biol* **14**, 27, doi:10.1186/1471-2121-14-27 (2013).
- 24 Jatana, N., Ascher, D. B., Pires, D. E. V., Gokhale, R. S. & Thukral, L. Human LC3 and GABARAP subfamily members achieve functional specificity via specific structural modulations. *Autophagy* **16**, 239-255, doi:10.1080/15548627.2019.1606636 (2020).
- 25 Shintani, T. *et al.* Apg10p, a novel protein-conjugating enzyme essential for autophagy in yeast. *The EMBO journal* **18**, 5234-5241, doi:10.1093/emboj/18.19.5234 (1999).
- 26 Li, Q. *et al.* Burkholderia pseudomallei survival in lung epithelial cells benefits from miRNA-mediated suppression of ATG10. *Autophagy* **11**, 1293-1307, doi:10.1080/15548627.2015.1058474 (2015).
- 27 Jo, Y. K. *et al.* Polypyrimidine tract-binding protein 1-mediated down-regulation of ATG10 facilitates metastasis of colorectal cancer cells. *Cancer Lett* **385**, 21-27, doi:10.1016/j.canlet.2016.11.002 (2017).
- 28 Zhao, Q. *et al.* Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic replicon Mediated Autophagy Flux and Innate Immunity. *Scientific reports* **7**, 11250, doi:10.1038/s41598-017-11105-3 (2017).
- 29 Zhang, M. Q., Li, J. R., Peng, Z. G. & Zhang, J. P. Differential Effects of Autophagy-Related 10 Protein on HCV Replication and Autophagy Flux Are Mediated by Its Cysteine(44) and Cysteine(135). *Front Immunol* **9**, 2176, doi:10.3389/fimmu.2018.02176 (2018).
- 30 Gonzalez-Rodriguez, P. *et al.* SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12. *Cell Death Dis* **11**, 69, doi:10.1038/s41419-020-2266-x (2020).
- 31 Ouyang, D. Y. *et al.* Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. *Autophagy* **9**, 20-32, doi:10.4161/auto.22397 (2013).
- 32 Sharma, S. *et al.* A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. *Transl Oncol* **1**, 141-147, doi:10.1593/tlo.08136 (2008).
- 33 Wible, D. J., Chao, H. P., Tang, D. G. & Bratton, S. B. ATG5 cancer mutations and alternative mRNA splicing reveal a conjugation switch that regulates ATG12-ATG5-ATG16L1 complex assembly and autophagy. *Cell Discov* **5**, 42, doi:10.1038/s41421-019-0110-1 (2019).
- 34 Fletcher, K. *et al.* The WD40 domain of ATG16L1 is required for its non-canonical role in lipidation of LC3 at single membranes. *The EMBO journal* **37**, doi:10.15252/embj.201797840 (2018).
- 35 Itoh, T. *et al.* Golgi-resident small GTPase Rab33B interacts with Atg16L and modulates autophagosome formation. *Molecular biology of the cell* **19**, 2916-2925, doi:E07-12-1231, doi:10.1091/mbc.E07-12-1231 (2008).

- 36 Jiang, T., Qin, B., He, J., Lin, S. & Ding, S. Three isoforms of the Atg16L1 protein contribute different autophagic properties. *Mol Cell Biochem* **378**, 257-266, doi:10.1007/s11010-013-1616-8 (2013).
- 37 Lystad, A. H. *et al.* Distinct functions of ATG16L1 isoforms in membrane binding and LC3B lipidation in autophagy-related processes. *Nat Cell Biol* **21**, 372-383, doi:10.1038/s41556-019-0274-9 (2019).
- 38 Sadaghian Sadabad, M. *et al.* The ATG16L1-T300A allele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients. *Gut* **64**, 1546-1552, doi:10.1136/gutjnl-2014-307289 (2015).
- 39 Gammoh, N. The multifaceted functions of ATG16L1 in autophagy and related processes. *J Cell Sci* **133**, doi:10.1242/jcs.249227 (2020).
- 40 Hampe, J. *et al.* A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* **39**, 207-211, doi:10.1038/ng1954 (2007).
- 41 Ishibashi, K. *et al.* Atg16L2, a novel isoform of mammalian Atg16L that is not essential for canonical autophagy despite forming an Atg12–5-16L2 complex. *Autophagy* **7**, 1500-1513, doi:10.4161/auto.7.12.18025 (2011).
- 42 Khor, B. *et al.* Distinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1. *J Immunol* **203**, 1820-1829, doi:10.4049/jimmunol.1800419 (2019).
- 43 Cuervo, A. M. & Dice, J. F. A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* **273**, 501-503 (1996).
- 44 Chi, C. *et al.* LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion. *Proc Natl Acad Sci U S A* **116**, 556-565, doi:10.1073/pnas.1808618116 (2019).
- 45 Fujiwara, Y. *et al.* Discovery of a novel type of autophagy targeting RNA. *Autophagy* **9**, 403-409, doi:10.4161/auto.23002 (2013).
- 46 Perez, L. *et al.* LAMP-2C Inhibits MHC Class II Presentation of Cytoplasmic Antigens by Disrupting Chaperone-Mediated Autophagy. *Journal of immunology* **196**, 2457-2465, doi:10.4049/jimmunol.1501476 (2016).
- 47 Wang, X. *et al.* PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell* **147**, 893-906, doi:10.1016/j.cell.2011.10.018 (2011).
- 48 Saifulina, D. *et al.* Miro proteins prime mitochondria for Parkin translocation and mitophagy. *The EMBO journal* **38**, doi:10.15252/embj.201899384 (2019).
- 49 Marongiu, R. *et al.* Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. *Hum Mutat* **28**, 98, doi:10.1002/humu.9472 (2007).
- 50 Sahashi, K. *et al.* In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites. *Nucleic Acids Res* **35**, 5995-6003, doi:10.1093/nar/gkm647 (2007).
- 51 Burns, M. P., Zhang, L., Rebeck, G. W., Querfurth, H. W. & Moussa, C. E. Parkin promotes intracellular Abeta1-42 clearance. *Hum Mol Genet* **18**, 3206-3216, doi:10.1093/hmg/ddp258 (2009).
- 52 Tan, M. M. X. *et al.* Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. *Brain* **142**, 2828-2844, doi:10.1093/brain/awz191 (2019).
- 53 Khaminets, A. *et al.* Regulation of endoplasmic reticulum turnover by selective autophagy. *Nature* **522**, 354-358, doi:10.1038/nature14498 (2015).
- 54 Kohno, S., Shiozaki, Y., Keenan, A. L., Miyazaki-Anzai, S. & Miyazaki, M. An N-terminal-truncated isoform of FAM134B (FAM134B-2) regulates starvation-induced hepatic selective ER-phagy. *Life Sci Alliance* **2**, doi:10.26508/lsa.201900340 (2019).

- 55 Hu, X. *et al.* Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. *EMBO J* **26**, 2755-2767, doi:10.1038/sj.emboj.7601707 (2007).
- 56 Yang, Y. S. & Strittmatter, S. M. The reticulons: a family of proteins with diverse functions. *Genome Biol* **8**, 234, doi:10.1186/gb-2007-8-12-234 (2007).